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CHAPTER I 
INTRODUCTION 
Quality care metrics provide a means to compare physicians across practices.  These 
measures are based on scientific evidence and attempt to reflect national guidelines for 
standard of care or typical practice parameters for disease management.  For example 
ambulatory care physicians are scored on the percentage of diabetic patients with good 
control as evidenced by a HgbA1c value less than 8 mg/dl.  Unfortunately these goals lack 
methods to adjust the contribution of patient health status to physician quality metrics 
outcomes.  Consequently, physicians generally give little credence to such data scoring 
results as inadequate measures of the quality of the care they are providing, often voicing 
the complaint that “my patients are sicker” as a cause for a lower quality metric than their 
colleagues.(1,2)  That sentiment is supported by evidence of patient co-morbidities 
exerting a stronger influence on quality metric outcomes than the effect of the 
physician.(3,4)   
Mortality risk and severity of illness scores have been used for decades as 
surrogates of patient disease burden to help risk adjust populations to analyze 
outcomes.(5–14)   Measures developed for outpatient populations have also typically relied 
on subjective descriptions of health status with variable success.(8,10,15–18)  The burden 
of data collection by measure of person time effort limits scalability of mortality indices for 
application across larger populations.(19)  Electronic Health Records (EHR) are 
tremendous sources of patient data, and can secondarily be used to provide information on 
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physicians through the patients they see, notes they write, diagnoses they make, and the 
orders they generate.  We hypothesized that EHR data could bridge the gap in defining 
components of an ambulatory mortality risk index in a systematic and replicable manner.  
There is a strong need for an automated implementation of an outpatient mortality risk 
prediction tool to support individual patient clinical decision support and provide risk 
adjustment for population management.   
Defining disease burden for an ambulatory population is complex because of greater 
variability in health status and the typical overall better health of the average outpatient 
population compared to the inpatient one.(20)  Limited duration risk indices such as the 
modified forms of the Charlson or Elixhauser, rely primarily on easily obtained 
administrative International Classification of Diseases Ninth Edition (ICD9) data and 
benefit from shorter term predictions in higher risk populations.(7,21)  The longer 
duration mortality risk indices, such as the (Lee 4 year Mortality Risk Index) Lee and 
Schonberg 5 year mortality risk index, share common components of patient age, gender, 
BMI, risk behaviors, co-morbid diseases and functional status.(10,12,22)  Functional status 
is unique to these measures and previously shown to predict mortality by itself.(10,11)   
Lee et al. described a 4 year Mortality Risk Index for outpatient populations over 50 
years of age that has been validated in two separate populations.(22)  To calculate 
mortality risk, the Lee model uses a 12-item patient survey of age, gender, presence of 4 
specific chronic diseases (Congestive Heart Failure (CHF), Chronic Lung Disease, Diabetes 
Mellitus (DM), Cancer), Body Mass Index (BMI), current smoking status and functional 
status to derive the risk score.  Functional status represents up to one third of the total 
score, thus potentially contributing a significant portion to a patient’s final mortality risk 
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estimate.  The Lee index has been used to better delineate frailty and vulnerability in older 
populations.(23)  Its application to a variable-aged outpatient population using EHR data 
has not been fully investigated.   
The Lee index is unique from the other longer duration tools in that all of its 
measures are available either directly from or with closely related proxies in the EHR.  
Measurement of functional status has been a part of Vanderbilt’s EHR via a clinical intake 
questionnaire administered to most outpatients as a part of Joint Commission on 
Accreditation of Healthcare Organizations (JCAHO) requirements in the form of a binary 
yes/no response.  While limited in comparison to the four functional status questions in the 
Lee it provides a reasonable proxy to this data. The Schonberg 5-year mortality risk score is 
the next most similar tool to the Lee but includes a subjective patient health status question 
and asks the patient to provide the number of hospitalizations for the prior year.  
Hospitalization data is challenging to collect from a particular EHR system given 
discontinuity in care as patients often seek care at different hospitals given changing health 
insurance, geographic relocations, and personal preferences.  
Overview of work presented in this thesis 
 
This thesis describes two studies evaluating the utility, discrimination and validity 
of an outpatient mortality risk score using an electronic adaptation of the Lee 4-year 
mortality risk model. 
In our initial study (CHAPTER II), we evaluated the accuracy of the Lee EHR-
adaptation (eLee) to predict 2-year mortality.  We implemented an EHR-adaptation of the 
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Lee in an outpatient primary care population using all patients seen by the fourteen study 
providers.  We calculated patient mortality risk from the date of enrollment and followed 
patients for up to two years for the outcome of death.  Using the total points assigned by 
the Lee and subsequent data of death at two years, discrimination of this model was 
determined by calculating the area under the receiver operator characteristic curve (AUC).   
We also applied a Cox proportional hazards model to three condensed stratums of 
mortality risk denoted as Low, Intermediate and High to represent clinically relevant and 
potentially actionable levels of risk.   To evaluate differences in physician patient panels, we 
compared the aggregate percentage of high and intermediate risk patients in each 
physician’s panel.  
In the second study (CHAPTER III), we compared the eLee representing our EHR-
adaptation to the original Lee survey for biases of information gathering and retrieval, and 
overall accuracy of survey and electronic data.  To better match the questions of functional 
status ascertained by the Lee survey, we implemented an expanded form of the functional 
status questions into the EHR and trained intake personnel on use of the new tool.   The 
new functionality consisted of an initial screening question of functional status that 
expanded to the four specific questions from the original Lee survey.   
To evaluate the similarities and differences of the Lee and Schonberg indices, we 
surveyed adult patients in ambulatory primary care clinics with a combined survey 
instrument.  Subsequently we applied the same eLee to the patients surveyed to directly 
compare the electronic equivalent score to the survey results.  We completed chart reviews 
of discrepancies between the survey and electronic results seen due to unrelated biases 
with both methodologies to establish an adjudicated standard.  Both the survey and the 
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electronic EHR-adaptation showed excellent correlation with the adjudicated standard 
with the electronic version.   
CHAPTER IV discusses the overall conclusions from the two studies along with their 
limitations.  We explore the potential future directions for applying this research in the 
clinical realms of individual level scores for personalized decision support and on the 
population level for risk adjustment for physician panels.    
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CHAPTER II 
USING AN ELECTRONICALLY ADAPTED MORTALITY RISK INDEX  
TO STRATIFY PRIMARY CARE PATIENTS  
Authors 
 Eugenia R. McPeek Hinz MD, Michael E Matheny MD MS MPH,  
Josh F Peterson MD MPH, Nancy M Lorenzi PhD MLS MA, Anderson Spickard III MD MS, 
Hui Nian MS, Qingxia Chen PhD, William M Gregg MD MS, Joshua C Denny MD MS 
 
Introduction and Background 
 Mortality risk and severity of illness scores have been used for decades as 
surrogates of patient disease burden to help risk adjust a population for utilization 
outcomes.(5–14)  Measures developed for outpatient populations have typically relied on 
subjective descriptions of health status, often assessed through patient survey, along with 
administrative data with variable success.(8,10,15–18)  The burden of data collection of 
these subjective components limits their scalability for larger populations.(19)  An 
automated implementation of an outpatient mortality risk prediction tool could enable 
individualized clinical decision support and risk adjustment for population management.  
Toward this end, we developed and evaluated an EHR-adaptation of the Lee et al. 4-year 
mortality index (eLee) in an outpatient primary care population and evaluated its ability to 
predict 2-year mortality.(22)  In addition, we evaluated mortality risk variation among providers’ 
patient populations.  
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 Some of the first attempts to characterize disease burden were developed for 
inpatient populations as a means to normalize patient effects on clinical outcomes.  The 
Severity of Illness Index was an early attempt to stratify patient co-morbidity as a means to 
understand resource utilization habits of doctors and cost for hospitalizations.(5,24–27) 
The well-known Charlson 1-year mortality risk measure, designed from hospitalized 
patient population has been widely used in modified forms to define risk of death based 
upon the cumulative measure of 13 ICD9 diseases categories.(7,9,28)  Extending the 
Charlson risk score, Elixhauser et al. defined more co-morbidity conditions using a large 
administrative data set to predict clinical outcomes for inpatient admissions.(21)  A 
common characteristic of these and similar measures is the use of diagnoses and 
demographics to calculate a risk of death.  These metrics have been well validated and 
benefit from the accuracy connected with short-term predictions in high risk populations. 
 Defining disease burden for an outpatient population can be more challenging 
because of greater variability in health status and diversity of reasons for seeking care.   In 
addition, longer-term mortality risk may be better predicted with functional status which 
indicates how well patients are physically coping with their cumulative disease burden.(11)   The 
Lee index was designed and validated for an outpatient populations over 50 years of age 
and uses a 12 item patient survey to measure age, gender, presence of 4 specific chronic 
diseases, body mass index (BMI), current smoking status and functional status to derive the 
risk score.  Functional status represents up to one third of the total score potentially 
contributing a significant portion to a patient’s final mortality risk estimate.  The Lee has 
been used to better delineate frailty and vulnerability in older populations.(23)  Its 
application to a variable-aged outpatient population using EHR data has not been fully 
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investigated.    
Methods 
Study Design 
We conducted this study among fourteen primary care physicians from a large 
academic medical center from September 1st 2009 to February 7th 2012.   The physicians 
were recruited by personal invitation by one of the authors (AS).  Four clinicians declined 
to participate.  For the other fourteen, informed consent was obtained during an 
introductory meeting.  Of the fourteen physicians, eleven had outpatient Internal Medicine 
practices, one was a Geriatrician and two were Internal Medicine/Pediatric doctors.  All 
patients seen by these providers were included the study.  Informed consent of participant 
patients was waived.  The Vanderbilt Institutional Review Board approved this project. 
Patient Cohort 
We required all subjects to have an outpatient visit during the initial cohort-defining 
period to eliminate patients seen during inpatient admissions.  The date of this visit 
established the beginning of follow up and the time point at which the mortality risk score 
was calculated.  To assure attribution fidelity of physician patient pairs, we ordered the 
sum of established outpatient visits (99211, 99212, 99213, 99214, 99215) for each patient 
by doctor and then correlated an outpatient visit during the enrollment period with their 
maximum corresponding study provider.   This process removes cross-covering physician 
care within suites and ensures that the physician most responsible for that patient was 
correctly attributed.   Manual review of twelve patients randomly selected from the original 
cohort found six patients were excluded appropriately.  Of the other six included in the 
 9 
 
final cohort, five had the primary care physician (PCP) of record as their study provider 
and one had a different PCP but clearly was being cared for by the algorithm identified 
provider.  This was verified by the presence of multiple outpatient visits with the algorithm 
provider as well as orders for labs and physical therapy by the same doctor.     
Data Collection 
Each physician was given a survey asking relevant provider characteristics 
including years in practice and gender.  We used the Learning Portfolio system, a web-
based application linked to the Vanderbilt EHR, to identify and collect data on all patients 
for whom the study physicians authored clinical notes (inpatient or outpatient).(29)   
Demographics, billing codes, and other structured data associated with each patient record 
were extracted from the EHR and the Enterprise Data Warehouse.  Patients were followed 
for the end point of mortality through February 7th 2012.   
We manually created lists of ICD9 codes for diabetes, cancer (excluding 
nonmelanoma skin cancer), lung disease and heart disease to match diagnoses in the Lee 
survey (Appendix A).  As a comparison metric, we also calculated the Deyo modified 
Charlson mortality risk index.  For the Charlson-Deyo version we relied on the originally 
reported ICD9 codes and updated them to reflect changes in coding since the time it was 
originally published (Appendix  B).(9)  Reliability of current smoking status limited 
complete identification of likely smokers.  Consequently we used ICD9 for tobacco use and 
flags from elsewhere in the EHR to identify smokers.   
Measurement of functional status was obtained from a structured (XML) clinic 
intake questionnaire.  This value represented the response to the following question, “Are 
you having any problems with walking, feeding yourself, bathing, dressing or other daily 
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activities, that you would like to discuss today?”  Spot verification for twenty charts 
confirmed that from the information available in the patient charts that 19 of these patients 
did have needs for assistance in functional activities documented in their record via clinic 
notes or clinical communications.   
Outcome Definition/Ascertainment 
All-cause mortality data was collected from the Social Security Death Index and 
internal EHR documentation for defining deaths.(30)  We performed secondary verification 
of all deaths and date of death by cross validation using National Death Index and outside 
sources such as Hospice records, funeral notices/obituaries or newspaper reports (for 
those more recently deceased).    
Electronic Mortality Risk Measurement 
We calculated the Lee for all patients using EHR data directly or as proxies for each 
of the elements captured by the Lee twelve-question survey.  The scores were determined 
directly for measures of age and gender.  Individuals with a single ICD9 code matching at 
least one of the disease proxy ICD9s for either index were considered to have the disease 
for purposes of risk calculation.  Table 1 shows the assigned risk factors, definition and 
points assigned along with demographics of our cohort. 
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Table 1: Demographics and Mortality Risk Point Attribution   
Risk Factor Risk Factor Definitions Points          Patient count (%) 
Age 18-59 + 
60-64 
65-69 
70-74 
75-79 
80-84 
>=85 
 
0 
1 
2 
3 
4 
5 
7 
 
1661 (49.9) 
373  (11.2) 
364  (10.9) 
316  (9.5) 
257  (7.8) 
198  (6.0) 
157  (4.7) 
Total (3326) 
Male Gender 
 
Men > 50 years             
Men < 50 years
†
 
2 
1 
867 (26.1) 
295 (8.9) 
Diabetes 250.* 1 809 (24.3) 
Cancer 151.*, 152.*, 153.*, 154.* 
162.*, 164.* 
189.*, 197.*, 199.* 
200.*, 201.*, 202.*, 203.* 
204.*, 205.* 
206.*, 207.*, 208.*, 209.* 
230.*, 231.* 
2 128 (3.9) 
Lung Disease 232, 233, 234 
416.9, 490.*, 491.*, 493.* 
398.41 
2 118 (3.6) 
Heart Disease 425.2 
428.* 
2 294 (8.8) 
 
BMI < 25 (only for 
patients ≥50 years†) 
 
Calculated from EHR  
Height and Weight 
Or 
Weight <=135 lbs
†
 
1 622 (18.7) 
Tobacco Use 
ICD9 305.1 
Internal EHR “smoker” flag 2 157 (4.7)                          
ADLs
†
 Structured EHR collection 2 244 (7.3%) 
Height Missing for 6.9% 
†
 denotes modification of the Lee model for cohort 
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In the Lee, impaired functional status has a range of values from 1 to 7.  In our EHR, 
functional status is only represented as a binary marker so we evaluated the data to 
determine the optimal equivalent value for this question for patients with impaired 
functional status.  The integrated discrimination improvement method was applied to the 
data set to determine a value of 2 (p = 0.040) as most effective proxy for the model.(31) 
Since the original validation study of the Lee risk score was completed on 
outpatients age ≥50 years, we made several empirical modifications to allow better 
application to patients under the age of 50.  Males under the age of 50 were given 1 risk 
point (instead of 2) and BMI < 25 did not contribute risk points considered a risk factor for 
those under the age of 50.  We calculated BMI using heights and weights from the EHR.  For 
patients with missing height information (6.9%), we assumed that an individual with a 
height of 5’ 2” and greater would have a BMI less than 25 when the measured weight was 
135 lbs or less. 
Statistical Analysis 
Baseline characteristics were compared using t-test for continuous variables, and 
the χ2 test for categorical variables.  Time in days from the patient’s enrollment visit 
between the dates of September 1st 2009 and February 7th 2010 to their death or end of 
follow up February 7th 2012 was thereafter determined.  Kaplan-Meier graphs for 
cumulative mortality were considered separately for risk strata.   
We subdivided the thirteen strata of mortality risk into three composite risk levels 
of low, intermediate and high risk.  Incidence rates by risk points were compared together 
for discovery of natural break points.  The incidence rate from the lowest risk strata 
doubled between points 5 and 6 and tripled as compared to baseline between 8 and 9 
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points.  Low risk was assigned percentage values 1-8% (0-5 points), intermediate risk 
between 9-20% (6-8 points) and high risk 28-64% (9+ points).      
To compare the risk of death between low, intermediate and high-risk subgroups, 
we calculated hazard ratios (HRs) using Cox proportional hazards models.  Since the Lee 
was derived using age, gender, BMI, smoking status and activities of daily living, these 
covariates were not adjusted for separately in the analysis.  We evaluated the impact of 
individual provider and physician gender as covariates in the Cox model.    
Model discrimination and calibration were assessed by calculating area under the 
receiver operator characteristic curve (AUC). The Charlson-Deyo model is intended for 1 
year risk definition and the Lee measure for patient age 50 and greater.  Consequently we 
compared the AUC for 1 and 2 years for the Charlson-Deyo analysis and by limiting to 
patients age of 50+ to contrast the original model intentions to our implementation.   
Finally we evaluated the contribution of age to the model and compared that to the Lee 
model in total. Integrated discrimination improvement (IDI) was also presented to 
compare the performances of different models in predicting two-year mortality. 
Specifically we first derived the predicted probabilities of two-year mortality for each 
patient from a univariable logistic regression on the risk score, and then calculated IDI 
based on the method proposed by Pencina, et al.(31) 
Aggregate practice panel mortality risk was evaluated for the study physicians.  Five 
physicians were eliminated for further study due to insufficient patient numbers (n< 75) 
due to part-time status.  We evaluated differences between physician’s practices for their 
overall patient risk profile compared to their gender by t-test.  We used a Cox proportional 
hazards model with outcome of death to study physician effect by including physician 
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identification as a fix effect.  Data analysis was completed within STATA version 11.1 
(StataCorp College Station TX) and R 2.14.1 (www.r-project.org/). 
Results 
The initial cohort identified in February of 2010 included 6859 patients who had 
had encounters with the 14 study physicians over the previous five months.  Only 3326 
patients remained after removing inpatient encounters and applying physician patient 
pairing refinement.  Mean age of the participants was 58.7 years (standard deviation [SD] 
16.5, range 18-102) with 65.1% females and 34.9% males.  Male physicians saw older 
patients on average than female physicians (61.5 vs. 54.4 years, p< 0.001).  Likewise, male 
physicians saw more high risk patients (5.9% vs. 2.3%, p< 0.001).   
 
  Table 2: Physician Practice Profile by Gender and Risk Stratum  
 Female 
Physicians 
Male 
Physicians 
Patient Gender 
     female 
     male < 50 
     male ≥ 50 
 
84.4% 
6.1% 
9.5% 
 
52.7% 
10.6% 
36.7% 
Mortality Risk 
      Low 
      Intermediate 
      High 
 
89.5% 
8.2% 
2.3% 
 
73.8% 
20.3% 
5.9% 
Mean Age (years±SD) 54.4 ±16.3 61.5 ±16.0 
 
A total of 103 patients died during the 2 year study period.  Figure 1 shows the 
cumulative mortality of each risk group.  The AUC for the Lee model continuous risk score 
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was 0.855.  For comparison, the AUC for the Charlson index at 2 years was 0.813 (Figure 2). 
The percentage of patients who died during the two years after enrollment as defined by 
their low to high risk stratum was 1.1%, 5.8% and 30.2%.(See Table 3) The Hazard ratio 
(HR) for intermediate risk was 6.0 (95% CI 3.7–9.7) with a p value of < 0.001 and 37.3 
(22.7– 61.2) for high risk with a p < 0.001.   Multivariable analysis adjusting for physician 
and gender identified one physician with significantly higher hazard ratio compared to 
peers.  Review of this physician’ four patients who died found these individuals were 
almost entirely classified as low risk due to younger age and had other diseases not 
captured by the Lee with significant co-morbidity, such as end stage liver disease.  There 
was significant evidence of difference in providers panel for Hazard Ratios which was 
verified by a likelihood ratio test with a (p = 0.017).(32) 
 
Figure 1: Kaplan-Meier Failure By Risk Stratums 
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To better understand the contribution of age and functional status to the mortality 
risk score, we compared the AUC values for the Lee model by age points and by exclusion of 
the functional status component.  With an AUC of 0.778 for age points alone, age yielded a 
significant proportion of the final model results but the total model improved the 
discriminatory power to 0.855 with a p < 0.001 when compared to age alone. This was also 
confirmed by a significant IDI of 0.079 between the two models (95% CI, 0.056 to 0.103, 
p<0.001).  The addition of a binary functional status marker mildly improved model 
discrimination, with an AUC without functional status 0.842 versus with of 0.855, and the 
corresponding IDI was estimated to be 0.018 (95% CI was 0.007 to 0.030, p=0.002)  
 
                          Table 3: Demographics by Mortality Risk 
Mortality Risk Number 
of 
Patients 
Percentage 
of the 
Population 
Number 
of Deaths 
2 Year 
Mortality 
Incidence   
Low (1-8%) 2657 79.9% 28 1.1% 
Intermediate  
(9-20%) 
520 15.6% 30 5.8% 
High (28-64%) 149 4.5% 45 30.2% 
       
 
The Charlson-Deyo AUC when applied to the same cohort study population for its 
intended model was 0.820 (95% CI 0.768-0.872) at one year.  The effectiveness of the 
Charlson-Deyo model decreases mildly at two years to 0.813 (95% CI 0.771–0.8549) but 
not significantly from the Lee model (p=0.089).  However, the corresponding IDI was 
estimated to be 0.069 (95% CI, 0.033 to 0.104) and suggested that Lee model was a 
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significant improvement in predicting two-year mortality compared to Charlson-Deyo 
model (p<0.001).  The Lee model for persons 50 years and older at two years gives an AUC 
of 0.843 (95% CI 0.801-0.885).  Overall the Lee outperformed the Charlson-Deyo at every 
cut point in the ROC curve at two years (Figure 2).   
 
Figure 2: AUC for Lee versus Charlson-Deyo at Two Years 
 
Heterogeneity in physician practice mortality profiles: 
Using the risk stratification definitions of low, intermediate and high risk, a little 
over twenty percent of the study cohort population fell into the higher risk categories. 
Physician practices showed significant differences in total percentage of intermediate and 
high mortality risks patients combined, with one physician with only 4.4% versus 30.4% 
risk for another of higher risk patients (p < 0.001). (See Table 4) Factors such as years in 
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practice were not associated with the mean age of their patient population (p= 0.25).  
Physician gender was a significant predictor of patient’s gender with respect to female 
physicians with a majority of female patient (83.8%) and males greater than age 50 with 
male primary care physicians (84.7%) (Table 2, p < 0.001).  
 
Table 4:Physician Demographics and Mortality Estimates of their patient panels 
 
Clinician Gende
r 
Years 
in 
Practic
e 
No. patients 
captured 
Mean Age of 
Practice(SD) 
Percentage 
High/Intermediat
e Risk 
A Female 16 347 57.2 ± 14.9 12.7     (9.6-16.6) 
B Male 20 1023 64.9 ± 13.9 30.4     (27.7 -33.3) 
C Male 16 220 56.8 ± 17.2 18.6     (14.1-24.3) 
  D* Male 14 316 63.4 ± 15.0 28.2     (23.5-33.4) 
E Female 8 90 50.9 ± 14.5   4.4     (1.7-10.9) 
F Female 8 278 52.4 ± 16.3   8.3     (5.6-12.1) 
G Female 6 518 54.6 ± 17.0 11.0     (8.6 - 14.0) 
   H** Male 5 352 51.9 ± 17.7 15.3     (12.0-19.5) 
I Male 3 89 62.8 ± 13.9 28.1     (18.8- 37.4) 
*Geriatrician      **Internal Medicine/Pediatric  
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Figure 3: eLee Risk Points by Physician 
 
Discussion 
This study demonstrates that using EHR and billing data the Lee Four Year Mortality 
Risk model successfully predicted 2-year mortality in an outpatient population. With an 
AUC of 0.855, our model had excellent discrimination consistent with original Lee results 
even when adapted to EHR proxies and applied to a general outpatient population.(33)  
This model offers a scalable electronically equivalent method to derive severity of illness 
for a general outpatient population comparable to the original survey version.  Given the 
growth of adoption of EHRs driven by the HITECH Act (Health Information Technology for 
Economic and Clinical Health Act), automatic implementation of electronic risk scores may 
allow more personalized care recommendations and provide greater insight into care 
quality.(34) 
To provide potentially clinically significant stratums of risk, we chose the use cut 
points of low, intermediate and high risk as done similarly before by Cagne et. al.  The 
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utility of these types of cut offs allows for an individual risk score which can then inform 
care on a personalized level.  For example, current population based recommendations for 
colonoscopy screening recommend stopping at the age of 75.  In our study, 21% of patients 
greater than 75 years of age fell into a low risk stratum and could potentially still benefit 
from screening.  Conversely patients in a higher risk category may benefit from different 
quality metric goals. 
We found differences in physician practices for proportion of higher risk patients in 
their panel not related to years in practice or mean age of the patients in the clinician panel.  
Such population differences are important when considering differences in patient 
outcomes by physician.  Low and intermediate risk patients may be a better population to 
consider physician quality measures by selecting the patients populations for which 
providers have more influence on outcomes.(35)  Robust risk adjustment methods are 
critical for effective provider profiles and engagement of clinicians.(36)   
Overall the Lee model performed slightly better than the Charlson-Deyo across a 
general outpatient population.  (, though this difference may not be clinically significant 
(AUC XX vs YY). Josh the IDI does indicate clinical significance)  The greatest differences in 
the Lee model’s effectiveness were seen in an older population, possibly due to the Lee 
inclusion of functional status and age in the model.  We noted that the Lee did not include 
certain life-threatening disease such as end stage liver disease, which adversely affected its 
performance for some younger patients.  Future work to extend this model would benefit 
from expanding the potential diseases considered in the model.   Additional incremental 
benefits may be seen with more detailed and structured data assessment of functional 
status exists.  
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This implementation of an electronic equivalent Lee index allowed determination of 
clinically relevant risk stratums.  The Lee does not include patient or physician assessment 
of health status as a component of the score and was thus more easily translated into an 
electronic version.  We are only aware of one other electronic implementation of the Lee 
index that evaluated effectiveness of colorectal cancer screening with mortality risk.(37)  
Ultimately, scalable risk defining models such as these have the potential to improve 
patient care through personalized clinical decision support and allow for risk adjustment to 
populations.     
        Limitations caution interpretation of these results. First, several changes were made 
to the original Lee algorithm to make it applicable to EHR data and to include patients 
under the age of 50.  These modifications to the model for BMI and male gender were 
determined clinically and have not been validated on a test cohort.  We also approximated 
functional status using a binary value instead of the more granular 7-point scale in the 
original Lee survey-based method.  By assigning a value of only 2 additional points for 
functional status, we likely underestimated the risk stratum for some members of the 
cohort.  If the true varied functional status values were available the significance of effect 
on the model would have likely been more evident. 
Finally we looked at only two years of mortality data instead of four years.  Even 
with the shorter time period of observation and changes in calculations, differences in 
magnitude of effect for the different risk stratums were evident and could be used 
clinically.  Future efforts should evaluate EHR based methods over longer time periods to 
determine if the effect seen thus far continues.  
Our study was small with only fourteen clinicians enrolled and 3326 of their 
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patients from one academic medical center evaluated.  We employed a definition of 
physician patient pairs based upon maximum number of established care visits for a study 
provider, increasing the probability of fidelity of who the primary care provider was for 
that patient.  However, this has a secondary effect of establishing a minimum level of data 
available for score determination that may serve to minimize missing data and represents 
patients who tend to see a provider more regularly.  Alternately patients without a primary 
care provider or who serially use acute care services may be underrepresented.   
Our application required only one of the study ICD9 diagnoses to have a point risk 
assigned.  As a result, disease risk points may have been given for a diagnosis that the 
patient may not actually have, since ICD9 codes can have poor positive predictive 
values.(38) Data for current smoking status was the most difficult to determine as there 
were multiple methods to define this data and underestimation of the population is likely 
for this marker. 
Conclusion 
We found that an EHR-derived 4-year mortality risk measure can successfully risk 
stratify an outpatient population and predict two year mortality outcomes.  Physician 
practices demonstrated differences in the numbers of intermediate and high-risk patients, 
but mortality outcomes were not physician-dependent.  Physician and patient same gender 
co-segregation contributed to aggregate co-morbidity of physician practices.  This measure 
was calculated using readily available EHR data and has potential for real-time 
implementation to assist in personalized clinical decision support and to adjust for the risk 
of physician practices to better understand their outcomes.  
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CHAPTER III 
AMBULATORY EVALUATION OF A 4-YEAR MORTALITY RISK INDEX  
BY SURVEY AND ELECTRONIC HEALTH RECORD ADAPATION  
Introduction 
In the modern age of medicine, better care for common co-morbidities such as heart 
disease, cancer and infection allows more adults to live active productive lives well into 
their eighth and ninth decades of life.(39)  As consequence, the boundaries of healthfulness 
are less well defined leading to potentially inappropriate care.  For example, previous 
studies have found application of age only screening recommendation led to screening of 
cancer patients with limited potential benefit or arbitrary limitation of cancer screening 
based upon age for patients in good health.(40,41) To respond to these changes, some 
clinical care guidelines are beginning to incorporate life expectancy into decisions of care 
recommendations.(42)  Longer duration validated prognostic tools exist but the 
reproducibility of their applications in a clinical setting is not well defined.(12,22)  
In Chapter II, we found the accuracy of our EHR-adaptation of the Lee index 
extended to a general adult population with an AUC of 0.855 at two years.  This value is 
very comparable to the original validated measure at four years of 0.82.  The two main 
limitations of this study were an unknown accuracy of the electronic proxy components 
used for determining co-morbid diseases and binary functional status indicator.  The 
application of ICD9s to capture the four diseases in that study may cause false positive 
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results due to poor positive predictive poor associated with ICD9s.(43,44)   
To evaluate the similarities and differences of the Lee survey versus the electronic 
EHR-adaptation, in this study, we surveyed adult patients in ambulatory primary care 
clinics with the original Lee survey instrument and compared the results to electronic 
scores.  To better match the questions of functional status with the survey, we 
implemented an expanded form of the functional status questions into the EHR.  We 
completed chart reviews of discrepancies between the survey and electronic results to 
define the biases associated with both methodologies to establish an adjudicated standard 
for comparison.    
Methods 
Overview 
We preformed a cross sectional analysis of primary care patient’s responses to a 
survey on measures of health status and compared these results to their corresponding 
electronic score for a four year mortality index.  We surveyed 415 primary care patients at 
the time of their clinic visit at a large academic medical center from November 2011 to 
February 2012 for the Lee 4-year and Schonberg 5-year mortality risk indices.  Patients 
consented for enrollment were verbally administered a combined 14 question survey.  We 
derived the electronic equivalent mortality risk score for each patient from EHR and billing 
data.  The Vanderbilt Institutional Review Board approved this project. 
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Survey Creation and Administration 
We used the 12 question Lee survey with minor changes to include former tobacco use as 
well as current tobacco use.  We then added two new questions on health status and the 
number of prior hospitalizations to allow for calculation of the Schonberg score after the 
Lee questions.  Thus, the final survey was a combination of the Lee and Schonberg  
(Appendix C).  The survey was administered verbally to patients by three study personnel 
(the author, a board-certified internist and two trained research assistants, who were 
observed intermittently by the author for quality control). 
 
Study Cohort 
We approached patients 18 years of age or older for survey participation generally 
immediately before or after their visits with the physician.  We collected age and gender for 
patients not surveyed but also seen in the clinic on the days of collection.  Physicians 
specialties for the two clinics where patients were interviewed included two geriatricians 
and the rest were primarily internal medicine(IM) or IM/Pediatric practices.  We consented 
and surveyed patients in the privacy of the examining room with the patient and any 
accompanying persons.  For patients unable to answer on their own, answers from the 
family or chaperone if familiar with the patient were used instead.  Dementia patients 
occasionally had family members who responded differently than the patient and their 
answers were recorded instead.   
 
Data Collection 
We transcribed the original survey results into a REDCap database 
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(http://www.project-redcap.org/) along with patient identifying data of name, date of 
encounter and medical record number (MRN).(45)  We exported REDCap survey data into 
the STATA statistical package and calculated the Lee and Schonberg prediction results from 
the survey (Table 5).  Equivalent electronic demographics, billing codes, and other 
structured data associated with each patient were extracted from the EHR and the 
Enterprise Data Warehouse in a similar fashion as described in Chapter 2.   
Common to the Lee and the Schonberg indices are components of functional status 
to their risk prediction scores.  In the prior study (Chapter II), we used an electronically-
completed clinic intake questionnaire to approximate functional status.  This questionnaire 
is filled out by clinic staff when a patient is brought into a clinic room and includes 
questions on reason for visit and included the question “Are you having any problems with 
walking, feeding yourself, bathing,  dressing, or other daily activities that you would like to 
talk about today” to address the patient’s functional status.  Upon completion, this data is 
represented in a codified form in XML in the EHR.  To better approximate the Lee measures 
electronically, we modified the XML-based Clinical Intake Questionnaire.  The prior 
question was changed into a two-part process which starts with a screening question:  
“Does the patient have any problems with walking 2-3 city blocks, bathing, dressing, or 
remembering important things?” This question captures the key elements of the four 
questions included in the Lee. If the patient responds in the affirmative, the form expands 
(using javascript elements in the web interface of our EHR) to ask four additional questions 
related specific measures of independence with activities of daily living (See Figure 3).  All 
clinical staff responsible for placing patients in examination rooms and completing the 
intake questionnaire were trained individually on the new changes.   
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Figure 4: Functionality Questions 
 
 
 
 
 
 
   
 
Adjudicated Standard 
 
Due to potential biases in the responses to the survey, we evaluated survey responses that 
differed from electronic ones using manual chart review.  Age, gender and electronic BMI 
measurements demonstrated close correlation and thus were not evaluated further.  For the four 
disease categories and tobacco use components of the Lee score, the primary author reviewed 
patient charts for discrepancies between survey responses and electronic data.  All cases of 
correlation by survey and electronic data for presence or absence of a measure were considered 
valid.  Chart review for evidence of disease included review of the patient problem list, physician 
notes, ICD9s or identification of medications or laboratory values consistent with disease 
processes.   
Chart review of discrepancies between responses for limitations of functionality between 
the survey and electronic forms were more challenging due to variable presence of sufficient 
1. Has a health or memory problem caused the patient to 
have any difficulty with bathing or showering?  
2. Has a health or memory problem caused the patient to 
have any difficulty with managing money such as paying 
bills or keeping track of expenses?  
3. Has a health problem caused the patient to have any 
difficulty with walking 2-3 city blocks without resting or 
assistance with a mobility device?  
4. Has a health or memory problem caused the patient to 
have any difficulty with pulling or pushing large objects, 
such as a large living room chair or small sofa? 
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chart documentation of the patient’s functional status/limitations.  Thus, a global assessment of 
presence or absence of “functional status impairment” was deemed sufficient. One reviewer 
reviewed all discrepant cases.  A second reviewer reviewed a random set of 50 of the 121 
discrepant cases for calculation of interrater agreement using Cohen’s Kappa and percent 
agreement.  
We created new disease and functional status control variables based upon the 
chart reviews of the discrepant cases to evaluate the strengths and limitations of the survey 
and electronic Lee adaptation.   Points for the adjudicated functional status control were 
given based upon the patient’s survey results for those cases where chart reviews were 
positive.    
Statistical Analysis 
Baseline characteristics of the patient cohort were compared using t-test for 
continuous variables, and the χ2 test for categorical variables.  All analyses assumed a two-
tailed distribution.  We compared the accuracy of the gold standard combined electronic 
and chart review Lee points to the EMR-derived elements to the actual results of the Lee 
survey points score using recall, precision, F-measure (2 * ((precision * recall)/(precision 
+recall)).  Pair wise population comparisons for binary presence of disease and smoking 
components were evaluated by McNemar’s exact score.  The Schonberg score, Lee, and 
eLee were compared to each other and to the adjudicated standard using Spearman 
correlation coefficient.  Data analysis was completed within STATA version 11.1 (StataCorp 
College Station TX) and R 2.14.1 (www.r-project.org/). 
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Results 
We interviewed a total of 410 patients in two primary care clinics from November 
2011 to February 2012.   One patient withdrew from the study after survey completion,  
leaving 409 study subjects.  Mean age of the participants was 58.3 years (standard 
deviation [SD] ± 17.3, range 19-99) with 58.2% females and 41.8% males (Table 5). 
Patient-reported BMI was moderately lower than that found electronically, 27.1 ± 5.1 
versus 29.4 ± 11.9.   
The Schonberg questions of health status and hospitalization yielded similar result 
as the original paper for health status and moderately more individuals, hospitalized twice 
in the past year, 11.5% in our survey versus 5.4% in the original cohort.  Spot review of 
charts for health status confirmed the subjective nature of this measure with three patients 
above the age of 80 reporting their health as excellent even though two had been 
hospitalized twice in the past year, one of whom was survey positive for cancer and the 
other patient not hospitalized had admitted trouble with memory and walking.  On the 
other end of the spectrum, three patients in their 50-60’s (59,68,57) described their health 
as poor with limited findings in their charts for significant diseases, besides well controlled 
diabetes and morbid obesity, or much by way of functional limitations.   
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Table 5: Demographics of Survey Population and Electronic Equivalent 
 Survey   n= 409 Electronic  n = 409 
Age (years) L, S 58.3 ± 17.6 58.3 ± 17.6 
Gender- Female L,S 58.2% 58.2% 
DM L,S 83  (20.3%) 90   (22.0%) 
Cancer L,S 50  (12.2%) 28   (6.9%) 
Lung Dz L,S 36  (8.8%) 26   (6.4%)  
CHF L 25  (6.1%) 31   (7.6%) 
Smoking L,S Never L,S        53.4% 
Former S        32.8% 
Current L,S     13.7% 
 
 
Yes/Current/flag    11.0% 
BMI (kg/m2) L,S 28.8 ± 7.7  
 
27.1 ± 5.1 for those with an 
EHR-defined height 
29.4 ± 11.9  
 
Missing height 13.7%  (56) 
ADL/Bathing deficitsS,L 50    (12.2%) 18   (4.9%) 
Walking deficitsS,L 145  (35.5%) 39   (10.7%) 
Managing Money deficitsL 42    (10.3%) 21   (5.7%) 
Trouble pushing large 
ObjectsL 
115  (28.2%) 35   (9.7%) 
Health StatusS Excellent(0)      11.3% 
Very Good(1)   31.0% 
Good(2)             34.2% 
Fair(3)                18.6% 
Poor(4)                4.9% 
 
HospitalizedS None     73.4% 
Once     15.1% 
Twice    11.5% 
 
Race  A     2.9% 
B     21.8% 
I       0.2% 
U     2.7% 
W    72.4%      
Values represent Mean±SD.  L = Lee 4-yr Model component;  S = Schonberg 5-yr Model 
component 
 
Table 6 shows the rates of Lee component measures in the survey compared to the 
electronic results.  Survey results reported presence of cancer in 12.2% and chronic lung 
disease 8.8% of patients.  These values exceeded the rates found electronically: cancer was 
found in 6.9% and chronic lung disease in 6.4% of patients, respectively.  Survey data was 
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similar to electronic data for the rates of diabetes mellitus (20.3% vs. 22.0%) and 
congestive heart failure (6.1% vs. 7.6%).  None of these subpopulations showed much 
population similarity by McNemar testing indicating significant differences in results. 
 
Table 6: Electronic Proxies Performance to Predict Survey Data 
 Recall Precision Accuracy F-measure McNemar’s 
Exact 
 
DM 82.2% 89.2% 93.9% 0.856 0.230 
Lung Dz 60.0% 41.7% 92.4% 0.492 0.071 
Cancer 75.0% 42.0% 91.2% 0.538 <0.001 
CHF 48.4% 64.0% 94.1% 0.552 0.308 
ADL’s 92.1% 33.3% 84.6% 0.490 <0.001 
Walk 89.7% 24.1% 72.1% 0.728 <0.001 
Push Large 
Object 
74.3% 22.6% 76.0% 0.346 <0.001 
Money 57.1% 28.6% 90.5% 0.406 0.001 
Bathing 72.2% 26.0% 89.7% 0.382 <0.001 
Smoke 
Current 
77.8% 62.5% 92.4% 0.694 
 
0.071 
 
* Yellow highlighted McNemar’s score for equality demonstrates the lack of correlation of the survey and 
EHR-adaptation of scores. 
 
Cancer Chart Review 
Review of the discrepant cancer cases found that of the 29 survey positive and 
electronic negative patients, 11 patients had remote history of cancer, greater than 10 or 
more  years ago, 5 had previously treated cancers but not recently classified as positive.  Of 
the other 13 cases, 7 had nonmelanoma skin cancers, 2 noncancerous resections and 6 had 
no specific chart evidence of cancer.  There were 7 survey negative for whom electronic 
evidence of cancer was found.  One of these had a cancer under treatment elsewhere, 5 had 
ICD9s for cancer testing, and 1 had a precancerous state with one older apparently 
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erroneous ICD9 denoting transformation.   After chart review 16 historical cancers by 
survey were reclassified as true positive and 6 electronic cases redefined as false positives. 
 
Table 7: Discrepant cases for Cancer by Survey versus Electronic Adaptation  
Cancer Electronic Positive Electronic Negative 
Survey Positive 21 
29  
-  11 remote cancer hx >10  
    years 
-  5 with cancer previously 
treated <10 years 
-  7 other skin cancers 
-  2 noncancerous resections 
-  6 no specific history found   
Negative for Cancer 
7  
- 1 positive cancer treated 
elsewhere 
- 5 noncancerous ICD9 for 
  testing 
- 1 precancerous state with 
one older transformation 
ICD9 from 5 years ago not 
repeated 
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Chronic Lung Disease Chart Review 
For the chronic lung disease cases, we reviewed 21 patients denoted survey positive 
and electronic negative (Table 8).  A majority (14 out of 21), were found by chart review to 
be ICD9 positive, mainly with ICD9 496 representing a general code Chronic Obstructive 
Pulmonary Disease (COPD) and two others with significant lung disease such as 
bronchiectasis. All of these were categorized as true positives on chart review.  These 
patients were false negatives in the electronic algorithm due to failure of capture of their 
ICD9 for these clinics in the electronic data warehouse.  For the other 5 individuals, 2 had 
mild lung disease and 3 had no chart evidence of lung disease.  The survey negative, 
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electronic positive subset consisted of 11 patients.  Seven patients were true positives for 
the electronic algorithm with 5 COPD patients and 2 other significant lung diseases, such as 
pulmonary fibrosis.  The remaining 4 patients had no chart evidence of disease.  
Table 8: Discrepant cases for Chronic Lung Disease by Survey versus Electronic 
Adaptation  
Chronic Lung Disease Electronic Positive Electronic Negative 
Survey Positive 15 
21 
-  14 with COPD by ICD9 in 
chart 
-  2 with other significant 
Lung disease 
-  2 with mild lung disease 
-  3 with no chart evidence of  
   disease 
Negative for Lung Disease 
11 
- 5 with COPD disease, 
- 2 other significant lung 
disease with  
   COPD ICD9 not relevant 
- 4 with no chart evidence of 
   significant Lung Disease 
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Diabetes Mellitus Chart Review 
Twenty-five diabetes mellitus (DM) cases were dissimilar.  Nine patients were 
survey positive but electronic negative cases, 3 were deemed positive by history and ICD9s, 
the remaining six were negative by chart review.  For the 16 survey negative, electronic 
positive cases, 12 were deemed positive with ICD9s and evidence of impaired fasting 
glucose or borderline Diabetes by chart review.  The other 4 cases were negative by chart 
review.  
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Table 9: Discrepant cases for Diabetes Mellitus by Survey versus Electronic 
Adaptation  
Diabetes Mellitus Electronic Positive Electronic Negative 
Survey Positive for DM 74 
9   
- 3 positive (1 with history of 
gestational DM) 
- 6 negative by chart review 
Negative for DM 
16 
- 12 considered impaired 
fasting glucose or borderline 
DM by chart review 
- 4 negative by chart review 
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Congestive Heart Failure Chart Review 
The final disease component under consideration was congestive heart failure 
(CHF). With a McNemar score of 0.308 between the survey and the electronic score 
directly, this measure showed the best population similarity of any of the Lee measures.   
For the 9 survey positive, electronic negative cases, 3 were positive for isolated CHF ICD9s 
mostly remotely and the other 6 lacked evidence of CHF, often having a history of non-CHF 
heart disease such as endocarditis, which is not considered in the Lee “CHF” category.  
Considering the 15 survey negative, electronic positive cases, 10 were positive by chart 
review for heart disease.  Chart evidence for CHF included diagnosis in patient notes 
including diastolic heart failure, a less than normal ejection fraction and current medication 
of diuretics and ace inhibitors.  The other 5 electronic positive, survey negative cases did 
not have CHF.   
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Table 10: Discrepant cases for CHF by Survey versus Electronic Adaptation  
CHF Electronic Positive Electronic Negative 
Survey Positive 
16 9  
- 3 positive for CHF mostly 
   remotely 5+ years ago 
- 6 negative or with other  
  significant heart disease  
Negative for CHF 
15 
- 10 positive for CHF by 
chart review 
- 5 with other significant 
heart disease not CHF 
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Smoking Chart Review 
Using the Schonberg version of the smoking question, we found that 53.4% of 
patients reported never using tobacco, 32.8% were former users and only 13.7% admitted 
current tobacco abuse.  The electronic measure for current tobacco identified 11.0% of the 
population as current smokers.  Simplifying  the survey data to “current” or “not currently”, 
using tobacco, the McNemar result is 0.071 suggesting the two populations are dissimilar 
(Table 11).  Review of patient charts for discrepant cases found of the 21 electronic 
negative but survey positive patients, 18 still smoking, 2 recently quit and 1 reportedly 
only used in college where the possibility of social tobacco use appeared to still be likely. Of 
the 10 survey-negative cases but electronically positive cases, 5 appeared to still be 
smoking by chart review and 5 appeared to have quit a few years back.   
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Table 11: Discrepant cases for Smoking by Survey versus Electronic Adaptation  
Smoking Electronic Positive Electronic Negative 
Survey Positive 35 
21 
- 18 currently smoking 
- 2 recently quit 
- 1 only used in college   
Negative for Smoking 
10 
- 5 smoking currently, 
generally just a few cigarette 
daily 
- 5 quit a few years back 
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Chart Review of Functional Status 
We found 174 (42.5%) individuals had positive responses to any of the four measures of 
functional status by the survey compared to only 63 (15.4%) by the intake questionnaire 
(p< 0.001) (Table 12).  Survey respondents reported the most trouble with walking several 
blocks for 145 individuals (35.5%) or inability with pushing a large object like a living 
room chair for 115 patients (28.2%).      
The clinic intake personnel completed the new intake questionnaire and answered 
the functional status question on 89.5% of patients in our survey.  While those without 
intake results appeared similar by age, mean 56.3 versus 56.0 years to patients with a 
response of “no” to the baseline functional status question, they tended to report better 
measures of health status by Lee survey, 1.36 versus 1.68 (p = 0.053).   
Electronic capture for these same measures found 39 (10.7%) with walking deficits 
and 35 (9.7%) with trouble pushing large objects.   For the survey measures of ADL’s and 
managing money the self reported deficits of 50 (12.2%) patients and 42 (10.3%) with 
electronic correlates of 18 (4.9%) and 21 (5.7%).   We reviewed the 5 patients that were 
survey negative but electronic positive. Chart review suggested three had functional status 
limitations.  The two electronic algorithm false positives included one individual with a 
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stress fracture and the other with no clear evidence of any limitations.   
 
Table 12: Discrepant cases for ADLs by Survey versus Electronic Adaptation  
ADL Electronic Positive Electronic Negative 
Survey Positive 58 
116 
- 44 considered positive 
- 72 without significant chart 
evidence   
Negative for ADL 
5 
- 3 considered positive 
- 2 negative with 1 with 
recent stress fracture injury 
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Review of survey positive but electronic negative cases found 44(37.9%) patients 
with some evidence of functional status limitations but a majority of patients 72 (62.1%) 
had no significant evidence by chart review to back up functional limitations.  For example, 
many cases ruled as negative by chart review had evidence of non-limiting chronic pain, 
such as knee osteoarthritis.  For these patients, no appreciable limitations could be 
determined as evidenced by review of the chart notes – many of the patients walked for 
exercising regularly or performed yard work, some even noting regular running programs 
or playing tennis. Additionally, exam notes supported lack of functional limitations with 
descriptions like normal gait and strength by the primary care, orthopedic or neurology 
physicians.   Many of the adjudicated positive cases had dementia or Parkinson’s disease 
with cognitive limitations inhibiting the ability to share functional status completely with 
the intake personnel.  See Tables 13 and 14 for descriptions of example patients.  
Review by a second practicing physician of a random set of 50 of the discordant 
cases for functional status, identified 18 cases positive for functional status limitations by 
chart review for a Kappa score of 0.48 consistent with moderate agreement between 
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reviewers.   For the 58 concordant cases by survey and electronic measure the patient self-
reported functional status was used for the adjudicated standard.   
Table 13:  Survey Positive Functional Status adjudicated as Negative for Impairment 
70s female Chart description by Geriatrician as Independent with ADLs and no 
memory impairment 
50s female with shoulder injury still working with e survey results positive for all 
four measures 
60s female with OA of knees walking only 2 hours a day instead of 3 hours 
60s male with ACL tear but still playing tennis and working in yard: complaint of 
trouble walking and pushing large objects 
50s female with knee pain but lives alone and works in real estate 
70s female Walking ¾ mile 4 times a week for exercise 
60s male semi retired plumber, jogs, plays golf and lifts weights for exercise 
 
Table 14:  Survey Positive Functional Status adjudicated as Positive for Impairment 
30s male with dwarfism complaints of trouble walking only 
80s male described as frail in clinical notes, also with mild memory 
impairment 
70s female with severe dementia, accompanied by daughter  
50s female with MS and recent fall with rib injury 
60s male Male with difficulty standing in chart notes 
 
Correlation of Survey and Electronic Indices of Predicted Mortality 
 The new adjudicated results for the four diseases, smoking and functional status were 
added together with the standard covariates of age, gender and BMI to provide an 
adjudicated control.   Subsequently we compared the control to the survey and electronic 
results for individual disease and smoking components (Tables 15 and 16).  The electronic 
algorithm for diabetes, cancer and CHF showed improved population correlation.  An 
undetermined error with chronic lung disease exportation from the EDW limited its 
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correlation to the survey results being more effective as well as smoking.    
 
Table 15: Adjudicated Control Standard versus Electronic Version 
 Recall Precision F-measure McNemar’s 
Exact 
DM 96.6% 95.6% 0.961 0.706 
Lung Dz 57.9% 84.6% 0.687 0.007 
Cancer 81.5% 78.6% 0.800 0.763 
CHF 89.7% 83.9% 0.867 0.480 
Smoke 
Current 
88.4% 67.6% 0.766 0.011 
 
 
 
Table 16:  Adjudicated Control Standard versus Survey Version 
 Recall Precision F-measure McNemar’s 
Exact 
DM 86.5% 92.8% 0.895 0.157 
Lung Dz 81.6% 86.1 0.838 0.564 
Cancer 96.4% 52.9% 0.683 <0.001 
CHF 65.5% 76.0% 0.703 0.317 
Smoke 
Current  
91.4% 94.6% 0.930 0.767 
 
 
 A total of five separate Lee scores were calculated for comparison.   They included:  
1) the original Lee 4-year survey score;  
2) the Schonberg 5-year survey score;  
3) the expanded functional status (0-7 points) electronic score; 
4) the 2-point original electronic score; 
5). and an adjudicated “gold” standard 
comprised of concordant survey and electronic positives and chart reviewed results for the 
four diseases categories, current smoking status, and functional impairment (as a the self 
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report survey score). 
We evaluated that difference in the total scores of the five separate scores using 
Spearman’s correlation coefficient (Table 17).  Using the adjudicated standard for 
comparison, the 2- point functional status and extended functional status scores had 
exactly the same score of 0.936 (95% CI 0.915-0.953) compared with the Lee survey with a 
score of 0.924 (95% CI 0.896-0.947).  All three versions of showed excellent correlation 
and overlapping confidence intervals indicating statistical equivalence of the three scores 
to each other.  The correlation of the 2-point and expanded electronic scores of 0.996 (95% 
CI 0.001-0.998) highlights the effective similarities of the functional status point 
attribution.  The Schonberg score against the original Lee score had a very good coefficient 
of 0.883 highlighting similarity of these scoring methods despite variations in the risk point 
assignment.      
 
Table 17: Spearman Correlation Coefficients 
Spearman 
(95% CI) 
Lee Survey  Schonberg  2 point eLee  0-7 points 
eLee  
“Gold”  Standard 
Score  
0.924 
(0.896-0.947)  
0.795 
(0.751-0.834)  
0.936 
(0.915-0.953)  
0.936 
(0.915-0.953)  
Lee Survey 
Score 
 0.883 
(0.858- 0.904)  
0.858 
(0.821- 0.889)  
0.856 
(0.820- 0.888)  
Schonberg Score    0.726 
(0.672-0.774)  
0.727 
(0.674-0.774)  
2 points eLee     0.995 
(0.991- 0.998)  
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Discussion 
This study demonstrates the correlation of an EHR-adaptation of the Lee 4-year 
index to the original survey validating the similarity of electronic version, with a Spearman 
correlation coefficient above 0.90 for the survey and the electronic versions against an 
adjudicated standard, both methods had excellent calibration.  The Lee EHR-adaptation 
index offers a scalable method for deriving disease burden in an outpatient population.   
According to chart review, both the survey and the electronic scores had errors in 
identification of co-morbidities and functional status.  On the survey side, we found that 
patients often did not identify their diseases as accurately as their medical record, as has 
been found in other studies in relation to health literacy.(46)  Survey respondents under-
identified a personal history of diabetes and congestive heart failure and over-identified a 
history of cancer.  The latter was typically due to recollections of non-melanoma skin 
cancers or testing for possible cancers that turned out to be negative.  For functional status, 
patients identified short-term or non-limiting functional limitations related to pain, 
possibly due to inadequate understandings of the questions being asked.  Capture of non-
visual limitations such as dementia was less effective by the measure of intake 
questionnaires and was identified with survey method frequently and is a known problem 
of clinical recognition.(47)  Expansion of the Lee EHR-adaptation to include dementia and 
medications provides an alternate means of more reliably obtaining that data when 
compared to the chart validation.         
Errors in the electronic version of the Lee derived from missing data  or false 
positives associated with use of a single ICD9 to identify a given disease.  We identified 
gaps in ICD9 data from the EDW in particular to the ICD9s for chronic lung disease that did 
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not correlate with information available for review in the EHR.  Review of the electronic 
capture by ICD9 for cancers in particular identified many patients with history of cancer 
more than 10 year before.  The benefit of assigning full point risk for remote cancer history 
warrants further study.  Simply limiting ICD9 data to less than five years and requiring 
multiple ICD9s to instantiate a disease category may decrease false positives.    
We implemented capture of functional status within our EHR by changing the clinic 
intake questionnaire to better mirror the Lee survey.  Correlation of the electronic 
extended functional status score versus a binary application of two points for functional 
status score were equivalent.  This finding supports the use of a single composite functional 
status question to capture this measure in a more efficient manner.  The lack of capture of 
the memory related functional status limitations via the intake form suggests an 
opportunity to use alternate means to screen for less visible functional limitations such as 
dementia and warrants consideration and further study. The lack of response to these 
questions may be biased by both social stigma of neurodegenerative diseases and the very 
presence of cognitive disease limiting patient’s ability to respond.  
 Limitations caution interpretation of these results.  First the size of the study is 
small with only 409 individuals and applied to a general Internal Medicine population.  Our 
mean age was 58.3 years similar to our previous study with a mean age of 58.7 years.  The 
original Lee survey included only patients > 50 years, and thus studied an older population 
(mean age 67 years).  While race is not a component of the original Lee index, the possible 
effect of our cohort composition is unknown and included almost twice the percentage of 
African Americans in this study versus the original Lee study.    
By using only subjective self reported functional status determinations, we had 
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limited means for verifying actual and amount of functional or mental disability.  This 
limited our determination of absolute truth and led to our use of an adjudicated standard 
group to represent the closest intentions to a gold standard.  Biases in respondent’s survey 
to diseases and functional status responses lead to variable over and under representation 
of the survey covariates.  The processes of clinic intake personnel appeared to limit capture 
of all patients with limitations especially for those with memory or less physically evident 
functionality problems.    
Conclusion 
We found that an EHR-derived 4-year mortality risk measures effectively correlates with 
the original Lee survey version for risk determination.  By identifying sources of possible errors 
in the electronic scoring algorithm, changes to improve the fidelity of capture risk covariates 
allows for improved more uniform scoring.  An EHR-adaptation approach to risk scoring has the 
benefit of automation allowing for possible inclusion in a clinical setting to inform patient care 
on an individual level or in aggregate on a physician panel or a clinic level for risk adjustment.     
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CHAPTER IV 
SUMMARY 
Summary of Findings 
These two studies explore the application of 4-year mortality risk score calculated 
from EHR data to define disease burden in a general ambulatory population.  The first 
study demonstrated that an electronic adaptation of the Lee index using EHR-derived data 
as proxies for the original survey data was able to predict patient death at two years.  
Physician practices differed considerably in proportions of higher predicted mortality risk 
individuals, due in part to gender co-segregation by patients to similar gender physicians.  
The second study compared direct patient survey-defined risk scores (using the original 
model) to the electronically-defined model.  We also studied the effectiveness of an 
expanded EHR form implementation to capture functional status, an element important in 
prior studies but not often captured well in EHRs.  The outcome of the latter study in 
defining ascertainment gaps informs on potential improvements for the EHR-adaptation.  
Compared to an adjudicated “Gold” standard formed through chart review, both the survey 
and electronic versions performed well.   Surprisingly, the expanded functional status form 
did not improve over the former binary implementation consisting of a simple screening 
question regarding the patients’ functional status.  These results favor the use of a single 
composite functionality question, although cognitive deficits may be inadequately captured 
through this method.  Future studies should investigate the application of a functional 
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status question with EHR-mined diagnoses such as dementia, which are less obvious to a 
casual observer and significantly impact functional status.     
These results demonstrate the effectiveness of an electronic algorithm to reproduce 
a previously validated mortality risk measure.  Such a tool has the potential for larger scale 
more automated implementation which could be applied in clinical settings for individual 
level decision support or in aggregate population level risk adjustment.  Methods that apply 
to a general adult population allows for risk adjustment in a complete fashion that 
implementation with a limited age would not.     
Limitations 
Limitations of these studies caution their interpretations.  The primary limitation of 
these studies is the relatively small numbers of individuals and physicians used for 
comparison, and the length of time (two vs. four years) for which mortality was assessed.    
We validated the ability of the eLee to discriminate risk of death for two years instead of 
four years as the original study.  The AUC value at two years for our model 0.86 was slightly 
higher than four year validation set of 0.82.  As our data saw a small decrease in the AUC 
from year one to year two, the outcome at four years would likely be decreased over the 
two year results. 
A second general limitation is derived from our electronic application of the Lee 
index applies outside of the intended and validated population of 50 years and greater.  As 
a consequence of broadening the index to a general adult population, we applied clinically 
modifications to the risk definitions for BMI and male gender under the age of 50 that are 
not validated for this portion of the population.    
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In regards to our electronic implementation, we used EHR data as proxy equivalents 
for survey components of diseases, BMI, smoking status and functional status.   For the 
electronic definition of diseases we substituted ICD9 codes and only required one value to 
be included.  The effect of this definition was to include patients with possibly errant 
diagnoses codes.   For the BMI proxy, a minority of patients did not have height information 
and even fewer of those were treated to risk points due to a weight of less than 135 pounds 
so the overall contribution to these changes is limited. For smoking status indicator we saw 
an improvement in the electronic capture of this measure from the initial study results in 
2009 to the values captured in 2012 due to EHR improvements to capture this information 
over time.  Finally for functional status, we used a binary value as a proxy of functional 
status with limited validation of its correspondence to measures of functional 
independence.  We evaluated the utility of an expanded electronic functional status 
measurement as well as the validity of these proxies in general in the final study.    
In the second study we, we applied a research survey tool in a clinical setting where 
time constraints limited the interview results to a simple answers.  The original study 
benefited from evaluating over 20 different measures of functional and disease status 
allowing more fine differentiation of true limitations and actual disease.  In our study 
patient health literacy was not included as a part of the study.  The subsequent chart 
review of discordant cases revealed significant disparity in patients understanding of the 
diseases they reported.            
To capture all possible Lee index responses on functional status we expanded the 
electronic capture of dependence measures within the clinic intake questionnaire.  Patient 
responses to these measures are captured by the medical assistants for either the legacy 
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method of one functional status question or with the newer version.  In the first study less 
than 8% of the population was electronically defined as positive.  Chart review of these 
patients did indeed support their dependence issues.   In the second study after training the 
clinic intake personnel on the new method, capture of electronic functional status 
limitations doubled.  Even though the mean age of the two studies was similar, the patient 
base of the second study included two geriatricians, so the possibility of increased 
functionality limitations for the second study population could be true.  Still the potential 
for a Hawthorne effect is also possible and should be considered in the difference in 
electronic capture.  Finally there also appeared to be some component of intake personnel 
ascertainment bias of patient robustness in capturing functional status needs 
electronically.  This was especially evidenced by the differences in better self defined health 
status values for those whose primary functional status question was not even answered in 
the first place.   Along with the intake personnel’s apparent judgment bias of physical 
functioning, there also some evidence by chart review of the survey positive electronically 
negative functional status patients, that limitations such as dementia were not noted 
electronically as well as the physical functional status limitations.  The second study in 
particular, identified the biases in data collection from both methods of scoring.  The 
electronic version benefits from being able to be iteratively improved and eventually 
automated. 
Future Directions 
These studies lay the groundwork in establishing the equivalency of the electronic 
Lee version to the original survey in form of measurement and to a lesser extent outcome 
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determinations.  The use of EHR data proxies appears to be as effective in categorizing for 
the components of the Lee with caveats identified in the second study to be noted.  The 
next step entails validating the eLee by applying the new model in a large general adult 
population.   Using the lessons of the second study modifications of the electronic algorithm 
for disease and functional status determination are warranted.  Specifically, disease 
definitions should include the following limitations of restricting ICD9 diseases inclusions 
to only those associated to the patient within the past five years and with at least two 
values in a disease group.  These changes should eliminate erroneous ICD9 values but need 
investigation to determine potential effect on sensitivity and positive predictive value for 
disease identification.  Further studies for broaden disease definitions may also be fruitful 
but need evaluation too before addition.  For instance the inclusion of lab results of 
hyperglycemia may aide in DM identification or the use of steroid inhaler medications to 
identify chronic lung disease.  Finally broadening of disease categories similar in 
composition to the Charlson-Deyo would increase the capture of potentially life 
threatening diseases that may be more common in younger populations and are not caught 
by the current four chronic disease subset.  The benefit of this approach would be the 
potential use of points already established in the Charlson formulation.  This type of 
modifications would require full statistical validation processes in both training and 
evaluation sets before use. 
Future larger studies using retrospective approaches to determine risk by EHR data 
and then to determine outcome of death in four years can appropriately validate the 
discrimination and calibration of this tool in a general internal medicine population.    
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Potentially future application of the eLee may inform patient level clinical decision support 
and in aggregate population level risk adjustment. 
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APPENDIX A    ICD9 for Lee Disease Determination 
icd9 dz_process 
494.1 LUNGDZ 
494 LUNGDZ 
494.0 LUNGDZ 
492.1 LUNGDZ 
492.2 LUNGDZ 
492.3 LUNGDZ 
492.4 LUNGDZ 
492.5 LUNGDZ 
202.80 CANCER 
428.1 CHF 
428.2 CHF 
428.3 CHF 
428.4 CHF 
428.9 CHF 
429.9 CHF 
250.0 DM 
250.00 DM 
250 DM 
250.01 DM 
250.02 DM 
250.03 DM 
250.10 DM 
250.1 DM 
250.11 DM 
250.12 DM 
250.13 DM 
250.20 DM 
250.2 DM 
250.21 DM 
250.22 DM 
250.23 DM 
250.30 DM 
250.3 DM 
250.31 DM 
250.32 DM 
250.33 DM 
250.40 DM 
250.4 DM 
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250.41 DM 
250.42 DM 
250.43 DM 
250.50 DM 
250.5 DM 
250.51 DM 
250.52 DM 
250.53 DM 
250.60 DM 
250.6 DM 
250.61 DM 
250.62 DM 
250.63 DM 
250.70 DM 
250.7 DM 
250.71 DM 
250.72 DM 
250.73 DM 
250.80 DM 
250.8 DM 
250.81 DM 
250.82 DM 
250.83 DM 
250.90 DM 
250.9 DM 
250.91 DM 
250.92 DM 
250.93 DM 
151 CANCER 
151.0 CANCER 
151.1 CANCER 
151.2 CANCER 
151.3 CANCER 
151.4 CANCER 
151.5 CANCER 
151.6 CANCER 
151.8 CANCER 
151.9 CANCER 
152 CANCER 
152.0 CANCER 
152.1 CANCER 
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152.2 CANCER 
152.3 CANCER 
152.8 CANCER 
152.9 CANCER 
153 CANCER 
153.1 CANCER 
154 CANCER 
154.1 CANCER 
162 CANCER 
162.0 CANCER 
162.2 CANCER 
162.3 CANCER 
162.4 CANCER 
162.5 CANCER 
162.8 CANCER 
162.9 CANCER 
164 CANCER 
164.0 CANCER 
164.1 CANCER 
164.2 CANCER 
164.3 CANCER 
164.8 CANCER 
164.9 CANCER 
189 CANCER 
189.0 CANCER 
189.1 CANCER 
189.2 CANCER 
189.3 CANCER 
189.8 CANCER 
189.9 CANCER 
197 CANCER 
197.0 CANCER 
197.1 CANCER 
197.2 CANCER 
197.3 CANCER 
197.4 CANCER 
197.5 CANCER 
197.6 CANCER 
197.7 CANCER 
197.8 CANCER 
199 CANCER 
 54 
 
199.0 CANCER 
199.1 CANCER 
200 CANCER 
200.0 CANCER 
200.1 CANCER 
200.2 CANCER 
200.3 CANCER 
200.4 CANCER 
200.5 CANCER 
200.6 CANCER 
200.7 CANCER 
200.8 CANCER 
201 CANCER 
202 CANCER 
202.0 CANCER 
202.1 CANCER 
202.2 CANCER 
202.3 CANCER 
202.4 CANCER 
202.5 CANCER 
202.6 CANCER 
202.7 CANCER 
202.8 CANCER 
202.9 CANCER 
203 CANCER 
203.0 CANCER 
204 CANCER 
204.0 CANCER 
204.1 CANCER 
205 CANCER 
205.0 CANCER 
205.1 CANCER 
206 CANCER 
207 CANCER 
207.0 CANCER 
207.1 CANCER 
207.2 CANCER 
208 CANCER 
209 CANCER 
209.0 CANCER 
209.1 CANCER 
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209.2 CANCER 
209.3 CANCER 
209.4 CANCER 
209.5 CANCER 
209.6 CANCER 
230 CANCER 
231 CANCER 
232 CANCER 
233 CANCER 
234 CANCER 
515 LUNGDZ 
491 LUNGDZ 
491.2 LUNGDZ 
491.21 LUNGDZ 
493 LUNGDZ 
493.2 LUNGDZ 
492 LUNGDZ 
492.0 LUNGDZ 
492.8 LUNGDZ 
493.82 LUNGDZ 
493.9 LUNGDZ 
398.91 CHF 
428.0 CHF 
428.1 CHF 
428.9 CHF 
305.1 TOBACCOUSE 
V15.82 TOBACCOUSE 
174 CANCER 
174.0 CANCER 
174.1 CANCER 
174.2 CANCER 
174.3 CANCER 
174.4 CANCER 
174.5 CANCER 
174.6 CANCER 
174.8 CANCER 
174.9 CANCER 
185 CANCER 
493.20 LUNGDZ 
493.2 LUNGDZ 
493.12 LUNGDZ 
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493.11 LUNGDZ 
493.10 LUNGDZ 
493.1 LUNGDZ 
493.00 LUNGDZ 
493.0 LUNGDZ 
496 LUNGDZ 
196 CANCER 
196.0 CANCER 
196.1 CANCER 
196.2 CANCER 
196.3 CANCER 
196.5 CANCER 
196.6 CANCER 
196.8 CANCER 
196.9 CANCER 
153.0 CANCER 
153.2 CANCER 
153.3 CANCER 
153.4 CANCER 
153.5 CANCER 
153.6 CANCER 
153.7 CANCER 
153.8 CANCER 
153.9 CANCER 
186 CANCER 
186.0 CANCER 
186.9 CANCER 
193 CANCER 
142 CANCER 
142.0 CANCER 
142.1 CANCER 
142.2 CANCER 
142.8 CANCER 
142.9 CANCER 
145 CANCER 
145.0 CANCER 
145.1 CANCER 
145.2 CANCER 
145.3 CANCER 
145.4 CANCER 
145.5 CANCER 
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145.6 CANCER 
145.8 CANCER 
145.9 CANCER 
195 CANCER 
195.0 CANCER 
195.1 CANCER 
195.2 CANCER 
195.3 CANCER 
195.4 CANCER 
195.5 CANCER 
195.8 CANCER 
198 CANCER 
198.0 CANCER 
198.1 CANCER 
198.2 CANCER 
198.3 CANCER 
198.4 CANCER 
198.5 CANCER 
198.6 CANCER 
198.7 CANCER 
198.8 CANCER 
198.81 CANCER 
198.82 CANCER 
198.89 CANCER 
147 CANCER 
147.0 CANCER 
147.1 CANCER 
147.2 CANCER 
147.3 CANCER 
147.8 CANCER 
147.9 CANCER 
180 CANCER 
180.0 CANCER 
180.1 CANCER 
180.8 CANCER 
180.9 CANCER 
172 CANCER 
172.1 CANCER 
172.2 CANCER 
172.3 CANCER 
172.4 CANCER 
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174.5 CANCER 
172.6 CANCER 
172.7 CANCER 
172.8 CANCER 
172.9 CANCER 
141 CANCER 
141.0 CANCER 
141.1 CANCER 
141.2 CANCER 
141.3 CANCER 
141.4 CANCER 
141.5 CANCER 
141.6 CANCER 
141.8 CANCER 
141.9 CANCER 
146 CANCER 
146.0 CANCER 
146.1 CANCER 
146.2 CANCER 
146.3 CANCER 
146.4 CANCER 
146.5 CANCER 
146.6 CANCER 
146.7 CANCER 
146.8 CANCER 
146.9 CANCER 
161 CANCER 
161.0 CANCER 
161.1 CANCER 
161.2 CANCER 
161.3 CANCER 
161.8 CANCER 
161.9 CANCER 
201 CANCER 
201.0 CANCER 
201.00 CANCER 
201.01 CANCER 
201.02 CANCER 
201.03 CANCER 
201.04 CANCER 
201.05 CANCER 
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201.06 CANCER 
201.07 CANCER 
201.08 CANCER 
201.1 CANCER 
201.10 CANCER 
201.11 CANCER 
201.12 CANCER 
201.13 CANCER 
201.14 CANCER 
201.15 CANCER 
201.16 CANCER 
201.17 CANCER 
201.18 CANCER 
201.2 CANCER 
201.20 CANCER 
201.21 CANCER 
201.22 CANCER 
201.23 CANCER 
201.24 CANCER 
201.25 CANCER 
201.26 CANCER 
201.27 CANCER 
201.28 CANCER 
201.4 CANCER 
201.40 CANCER 
201.41 CANCER 
201.42 CANCER 
201.43 CANCER 
201.44 CANCER 
201.45 CANCER 
201.47 CANCER 
201.48 CANCER 
201.5 CANCER 
201.50 CANCER 
201.51 CANCER 
201.52 CANCER 
201.53 CANCER 
201.54 CANCER 
201.55 CANCER 
201.56 CANCER 
201.57 CANCER 
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201.58 CANCER 
201.6 CANCER 
201.60 CANCER 
201.61 CANCER 
201.62 CANCER 
201.63 CANCER 
201.64 CANCER 
201.65 CANCER 
201.66 CANCER 
201.67 CANCER 
201.68 CANCER 
201.7 CANCER 
201.70 CANCER 
201.71 CANCER 
201.72 CANCER 
201.73 CANCER 
201.74 CANCER 
201.75 CANCER 
201.76 CANCER 
201.77 CANCER 
201.78 CANCER 
201.9 CANCER 
201.90 CANCER 
201.91 CANCER 
201.92 CANCER 
201.93 CANCER 
201.94 CANCER 
201.95 CANCER 
201.96 CANCER 
201.97 CANCER 
201.98 CANCER 
493.21 LUNGDZ 
493.22 LUNGDZ 
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APPENDIX B  Charlson-Deyo  ICD9 and Point Value Determinations 
icd9 dz point_value 
410 MI 1 
410.1 MI 1 
410.2 MI 1 
410.3 MI 1 
410.4 MI 1 
410.5 MI 1 
410.6 MI 1 
410.7 MI 1 
410.8 MI 1 
410.9 MI 1 
411 MI 1 
411.1 MI 1 
411.89 MI 1 
412 MI 1 
429.7 MI 1 
398.91 CHF 1 
425.2 CHF 1 
428 CHF 1 
428 CHF 1 
428.2 CHF 1 
428.21 CHF 1 
428.22 CHF 1 
428.3 CHF 1 
428.32 CHF 1 
428.4 CHF 1 
428.9 CHF 1 
440.2 PVD 1 
440.21 PVD 1 
440.23 PVD 1 
443.1 PVD 1 
443.9 PVD 1 
997.7 PVD 1 
430 Cerebrovascular_dz 1 
431 Cerebrovascular_dz 1 
432 Cerebrovascular_dz 1 
432.9 Cerebrovascular_dz 1 
433 Cerebrovascular_dz 1 
433 Cerebrovascular_dz 1 
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433.1 Cerebrovascular_dz 1 
433.2 Cerebrovascular_dz 1 
436 Cerebrovascular_dz 1 
437 Cerebrovascular_dz 1 
437 Cerebrovascular_dz 1 
437.1 Cerebrovascular_dz 1 
437.3 Cerebrovascular_dz 1 
437.4 Cerebrovascular_dz 1 
437.5 Cerebrovascular_dz 1 
437.9 Cerebrovascular_dz 1 
438 Cerebrovascular_dz 1 
438.8 Cerebrovascular_dz 1 
438.89 Cerebrovascular_dz 1 
438.9 Cerebrovascular_dz 1 
747.81 Cerebrovascular_dz 1 
997.02 Cerebrovascular_dz 1 
290 Dementia 1 
290 Dementia 1 
290.1 Dementia 1 
290.2 Dementia 1 
290.3 Dementia 1 
290.41 Dementia 1 
290.42 Dementia 1 
294.1 Dementia 1 
331.19 Dementia 1 
331.82 Dementia 1 
416.9 Chronic_Pulmonary_Dz 1 
490 Chronic_Pulmonary_Dz 1 
491 Chronic_Pulmonary_Dz 1 
491.2 Chronic_Pulmonary_Dz 1 
491.21 Chronic_Pulmonary_Dz 1 
493 Chronic_Pulmonary_Dz 1 
493 Chronic_Pulmonary_Dz 1 
439.1 Chronic_Pulmonary_Dz 1 
493.2 Chronic_Pulmonary_Dz 1 
492 Chronic_Pulmonary_Dz 1 
492 Chronic_Pulmonary_Dz 1 
492.8 Chronic_Pulmonary_Dz 1 
710.1 Connective_tissue_Dz 1 
710.9 Connective_tissue_Dz 1 
373.34 Connective_tissue_Dz 1 
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695.4 Connective_tissue_Dz 1 
530.2 Ulcer_Dz 1 
531 Ulcer_Dz 1 
531 Ulcer_Dz 1 
531.01 Ulcer_Dz 1 
531.1 Ulcer_Dz 1 
531.1 Ulcer_Dz 1 
531.11 Ulcer_Dz 1 
531.2 Ulcer_Dz 1 
531.2 Ulcer_Dz 1 
531.21 Ulcer_Dz 1 
531.3 Ulcer_Dz 1 
531.3 Ulcer_Dz 1 
531.4 Ulcer_Dz 1 
531.4 Ulcer_Dz 1 
531.41 Ulcer_Dz 1 
531.5 Ulcer_Dz 1 
531.5 Ulcer_Dz 1 
531.51 Ulcer_Dz 1 
531.6 Ulcer_Dz 1 
531.6 Ulcer_Dz 1 
531.61 Ulcer_Dz 1 
531.7 Ulcer_Dz 1 
531.7 Ulcer_Dz 1 
531.71 Ulcer_Dz 1 
531.9 Ulcer_Dz 1 
531.9 Ulcer_Dz 1 
532 Ulcer_Dz 1 
532 Ulcer_Dz 1 
532.01 Ulcer_Dz 1 
532.1 Ulcer_Dz 1 
532.1 Ulcer_Dz 1 
532.11 Ulcer_Dz 1 
532.2 Ulcer_Dz 1 
532.2 Ulcer_Dz 1 
532.21 Ulcer_Dz 1 
532.2 Ulcer_Dz 1 
532.3 Ulcer_Dz 1 
532.31 Ulcer_Dz 1 
532.4 Ulcer_Dz 1 
532.4 Ulcer_Dz 1 
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532.41 Ulcer_Dz 1 
532.5 Ulcer_Dz 1 
532.5 Ulcer_Dz 1 
532.51 Ulcer_Dz 1 
532.6 Ulcer_Dz 1 
532.6 Ulcer_Dz 1 
532.61 Ulcer_Dz 1 
532.7 Ulcer_Dz 1 
532.7 Ulcer_Dz 1 
532.71 Ulcer_Dz 1 
532.9 Ulcer_Dz 1 
532.9 Ulcer_Dz 1 
532.91 Ulcer_Dz 1 
533 Ulcer_Dz 1 
533 Ulcer_Dz 1 
533.01 Ulcer_Dz 1 
533.1 Ulcer_Dz 1 
533.1 Ulcer_Dz 1 
533.11 Ulcer_Dz 1 
533.2 Ulcer_Dz 1 
533.2 Ulcer_Dz 1 
533.21 Ulcer_Dz 1 
533.2 Ulcer_Dz 1 
533.3 Ulcer_Dz 1 
533.31 Ulcer_Dz 1 
533.4 Ulcer_Dz 1 
533.4 Ulcer_Dz 1 
533.41 Ulcer_Dz 1 
533.5 Ulcer_Dz 1 
533.5 Ulcer_Dz 1 
533.51 Ulcer_Dz 1 
533.6 Ulcer_Dz 1 
533.6 Ulcer_Dz 1 
533.61 Ulcer_Dz 1 
533.7 Ulcer_Dz 1 
533.7 Ulcer_Dz 1 
533.71 Ulcer_Dz 1 
533.9 Ulcer_Dz 1 
533.9 Ulcer_Dz 1 
533.91 Ulcer_Dz 1 
534 Ulcer_Dz 1 
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534 Ulcer_Dz 1 
534.01 Ulcer_Dz 1 
534.1 Ulcer_Dz 1 
534.1 Ulcer_Dz 1 
534.11 Ulcer_Dz 1 
534.2 Ulcer_Dz 1 
534.2 Ulcer_Dz 1 
534.21 Ulcer_Dz 1 
534.2 Ulcer_Dz 1 
534.3 Ulcer_Dz 1 
534.31 Ulcer_Dz 1 
534.4 Ulcer_Dz 1 
534.4 Ulcer_Dz 1 
534.41 Ulcer_Dz 1 
534.5 Ulcer_Dz 1 
534.5 Ulcer_Dz 1 
534.51 Ulcer_Dz 1 
534.6 Ulcer_Dz 1 
534.6 Ulcer_Dz 1 
534.61 Ulcer_Dz 1 
534.7 Ulcer_Dz 1 
534.7 Ulcer_Dz 1 
534.71 Ulcer_Dz 1 
534.9 Ulcer_Dz 1 
534.9 Ulcer_Dz 1 
534.91 Ulcer_Dz 1 
347.1 Cerebrovascular_dz 1 
362.34 Cerebrovascular_dz 1 
430 Cerebrovascular_dz 1 
431 Cerebrovascular_dz 1 
432 Cerebrovascular_dz 1 
432.1 Cerebrovascular_dz 1 
432.9 Cerebrovascular_dz 1 
434.01 Cerebrovascular_dz 1 
434.11 Cerebrovascular_dz 1 
434.91 Cerebrovascular_dz 1 
435 Cerebrovascular_dz 1 
435 Cerebrovascular_dz 1 
435.1 Cerebrovascular_dz 1 
435.2 Cerebrovascular_dz 1 
435.3 Cerebrovascular_dz 1 
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435.9 Cerebrovascular_dz 1 
438 Cerebrovascular_dz 1 
250 DM 1 
250 DM 1 
250 DM 1 
250.01 DM 1 
250.02 DM 1 
250.03 DM 1 
250.1 DM 1 
250.1 DM 1 
250.11 DM 1 
250.12 DM 1 
250.13 DM 1 
250.2 DM 1 
250.2 DM 1 
250.21 DM 1 
250.22 DM 1 
250.23 DM 1 
250.3 DM 1 
250.3 DM 1 
250.31 DM 1 
250.32 DM 1 
250.33 DM 1 
196.2 Metastatic_Solid_Tumor 6 
196 Metastatic_Solid_Tumor 6 
456.3 Mod_Severe_Liver_Dz 3 
456.2 Mod_Severe_Liver_Dz 3 
456.1 Mod_Severe_Liver_Dz 3 
572.8 Mod_Severe_Liver_Dz 3 
572.3 Mod_Severe_Liver_Dz 3 
250.8 DM 1 
250.8 DM 1 
250.81 DM 1 
250.82 DM 1 
250.83 DM 1 
250.9 DM_end_Organ_Damage 2 
250.9 DM_end_Organ_Damage 2 
250.91 DM_end_Organ_Damage 2 
250.92 DM_end_Organ_Damage 2 
250.93 DM_end_Organ_Damage 2 
342 Hemiplegia 2 
 67 
 
342 Hemiplegia 2 
342.1 Hemiplegia 2 
342.8 Hemiplegia 2 
342.9 Hemiplegia 2 
343.1 Hemiplegia 2 
343.4 Hemiplegia 2 
344 Hemiplegia 2 
438.2 Hemiplegia 2 
438.2 Hemiplegia 2 
438.5 Hemiplegia 2 
585.3 Mod_Severe_Renal_Dz 2 
585.4 Mod_Severe_Renal_Dz 2 
585.5 Mod_Severe_Renal_Dz 2 
585.6 Mod_Severe_Renal_Dz 2 
585.9 Mod_Severe_Renal_Dz 2 
586 Mod_Severe_Renal_Dz 2 
587 Mod_Severe_Renal_Dz 2 
588 Mod_Severe_Renal_Dz 2 
582 Mod_Severe_Renal_Dz 2 
581 Mod_Severe_Renal_Dz 2 
581.1 Mod_Severe_Renal_Dz 2 
581.2 Mod_Severe_Renal_Dz 2 
581.8 Mod_Severe_Renal_Dz 2 
581.81 Mod_Severe_Renal_Dz 2 
581.89 Mod_Severe_Renal_Dz 2 
581.9 Mod_Severe_Renal_Dz 2 
250.4 DM_end_Organ_Damage 2 
250.4 DM_end_Organ_Damage 2 
250.41 DM_end_Organ_Damage 2 
250.42 DM_end_Organ_Damage 2 
250.43 DM_end_Organ_Damage 2 
250.5 DM_end_Organ_Damage 2 
250.5 DM_end_Organ_Damage 2 
250.51 DM_end_Organ_Damage 2 
250.52 DM_end_Organ_Damage 2 
250.53 DM_end_Organ_Damage 2 
250.6 DM_end_Organ_Damage 2 
250.6 DM_end_Organ_Damage 2 
250.61 DM_end_Organ_Damage 2 
250.62 DM_end_Organ_Damage 2 
250.63 DM_end_Organ_Damage 2 
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250.7 DM_end_Organ_Damage 2 
250.7 DM_end_Organ_Damage 2 
250.71 DM_end_Organ_Damage 2 
250.72 DM_end_Organ_Damage 2 
250.73 DM_end_Organ_Damage 2 
151 tumor 2 
151 tumor 2 
151.1 tumor 2 
151.2 tumor 2 
151.3 tumor 2 
151.4 tumor 2 
151.5 tumor 2 
151.6 tumor 2 
151.8 tumor 2 
151.9 tumor 2 
152 tumor 2 
152 tumor 2 
152.1 tumor 2 
152.2 tumor 2 
152.3 tumor 2 
152.8 tumor 2 
152.9 tumor 2 
153 tumor 2 
153.1 tumor 2 
154 tumor 2 
154.1 tumor 2 
162 tumor 2 
162 tumor 2 
162.2 tumor 2 
162.3 tumor 2 
162.4 tumor 2 
162.5 tumor 2 
162.8 tumor 2 
162.9 tumor 2 
164 tumor 2 
164 tumor 2 
164.1 tumor 2 
164.2 tumor 2 
164.3 tumor 2 
164.8 tumor 2 
164.9 tumor 2 
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189 tumor 2 
189 tumor 2 
189.1 tumor 2 
189.2 tumor 2 
189.3 tumor 2 
189.8 tumor 2 
189.9 tumor 2 
209 tumor 2 
209 tumor 2 
209.1 tumor 2 
209.2 tumor 2 
209.3 tumor 2 
209.4 tumor 2 
209.5 tumor 2 
209.6 tumor 2 
230 tumor 2 
230.1 tumor 2 
230.2 tumor 2 
230.3 tumor 2 
230.4 tumor 2 
230.5 tumor 2 
230.6 tumor 2 
230.7 tumor 2 
230.8 tumor 2 
230.9 tumor 2 
231 tumor 2 
231.1 tumor 2 
231.2 tumor 2 
231.8 tumor 2 
231.9 tumor 2 
232 tumor 2 
232 tumor 2 
232.1 tumor 2 
232.2 tumor 2 
232.3 tumor 2 
232.4 tumor 2 
232.5 tumor 2 
232.6 tumor 2 
232.7 tumor 2 
232.8 tumor 2 
232.9 tumor 2 
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233 tumor 2 
233 tumor 2 
233.1 tumor 2 
233.2 tumor 2 
233.3 tumor 2 
233.3 tumor 2 
233.31 tumor 2 
233.39 tumor 2 
233.4 tumor 2 
233.5 tumor 2 
233.6 tumor 2 
233.7 tumor 2 
233.9 tumor 2 
234 tumor 2 
234 tumor 2 
234.8 tumor 2 
203 tumor 2 
203 tumor 2 
204 tumor 2 
204 tumor 2 
204.1 tumor 2 
205 tumor 2 
205 tumor 2 
205.1 tumor 2 
206 tumor 2 
207 tumor 2 
207 tumor 2 
207.1 tumor 2 
207.2 tumor 2 
208 tumor 2 
200 tumor 2 
200 tumor 2 
200.1 tumor 2 
200.2 tumor 2 
200.3 tumor 2 
200.4 tumor 2 
200.5 tumor 2 
200.6 tumor 2 
200.7 tumor 2 
200.8 tumor 2 
201 tumor 2 
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201 tumor 2 
201 tumor 2 
201.01 tumor 2 
201.02 tumor 2 
201.03 tumor 2 
201.04 tumor 2 
201.05 tumor 2 
201.06 tumor 2 
201.07 tumor 2 
201.08 tumor 2 
201.1 tumor 2 
201.1 tumor 2 
201.11 tumor 2 
201.12 tumor 2 
201.13 tumor 2 
201.14 tumor 2 
201.15 tumor 2 
201.16 tumor 2 
201.17 tumor 2 
201.18 tumor 2 
201.2 tumor 2 
201.2 tumor 2 
201.21 tumor 2 
201.22 tumor 2 
201.23 tumor 2 
201.24 tumor 2 
201.25 tumor 2 
201.26 tumor 2 
201.27 tumor 2 
201.28 tumor 2 
201.4 tumor 2 
201.4 tumor 2 
201.41 tumor 2 
201.42 tumor 2 
201.43 tumor 2 
201.44 tumor 2 
201.45 tumor 2 
201.46 tumor 2 
201.47 tumor 2 
201.48 tumor 2 
201.5 tumor 2 
 72 
 
201.5 tumor 2 
201.51 tumor 2 
201.52 tumor 2 
201.53 tumor 2 
201.54 tumor 2 
201.55 tumor 2 
201.56 tumor 2 
201.57 tumor 2 
201.58 tumor 2 
201.6 tumor 2 
201.6 tumor 2 
201.61 tumor 2 
201.62 tumor 2 
201.63 tumor 2 
201.64 tumor 2 
201.65 tumor 2 
201.66 tumor 2 
201.67 tumor 2 
201.68 tumor 2 
201.7 tumor 2 
201.7 tumor 2 
201.71 tumor 2 
201.72 tumor 2 
201.73 tumor 2 
201.74 tumor 2 
201.75 tumor 2 
201.76 tumor 2 
201.77 tumor 2 
201.78 tumor 2 
201.9 tumor 2 
201.9 tumor 2 
201.91 tumor 2 
201.92 tumor 2 
201.93 tumor 2 
201.94 tumor 2 
201.95 tumor 2 
201.96 tumor 2 
201.97 tumor 2 
201.98 tumor 2 
202 tumor 2 
202 tumor 2 
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202.1 tumor 2 
202.2 tumor 2 
202.3 tumor 2 
202.4 tumor 2 
202.5 tumor 2 
202.6 tumor 2 
202.7 tumor 2 
202.8 tumor 2 
202.9 tumor 2 
456.2 Mod_Severe_Liver_Dz 3 
522.8 Mod_Severe_Liver_Dz 3 
571 Mod_Severe_Liver_Dz 3 
571.3 Mod_Severe_Liver_Dz 3 
571.5 Mod_Severe_Liver_Dz 3 
571.8 Mod_Severe_Liver_Dz 3 
571.9 Mod_Severe_Liver_Dz 3 
572 Mod_Severe_Liver_Dz 3 
573 Mod_Severe_Liver_Dz 3 
573.1 Mod_Severe_Liver_Dz 3 
573.9 Mod_Severe_Liver_Dz 3 
197 Metastatic_Solid_Tumor 6 
197 Metastatic_Solid_Tumor 6 
197.1 Metastatic_Solid_Tumor 6 
197.2 Metastatic_Solid_Tumor 6 
197.3 Metastatic_Solid_Tumor 6 
197.4 Metastatic_Solid_Tumor 6 
197.5 Metastatic_Solid_Tumor 6 
197.6 Metastatic_Solid_Tumor 6 
197.7 Metastatic_Solid_Tumor 6 
197.8 Metastatic_Solid_Tumor 6 
198 Metastatic_Solid_Tumor 6 
198 Metastatic_Solid_Tumor 6 
198.1 Metastatic_Solid_Tumor 6 
198.2 Metastatic_Solid_Tumor 6 
198.3 Metastatic_Solid_Tumor 6 
198.4 Metastatic_Solid_Tumor 6 
198.5 Metastatic_Solid_Tumor 6 
198.6 Metastatic_Solid_Tumor 6 
198.7 Metastatic_Solid_Tumor 6 
198.8 Metastatic_Solid_Tumor 6 
198.81 Metastatic_Solid_Tumor 6 
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198.82 Metastatic_Solid_Tumor 6 
198.89 Metastatic_Solid_Tumor 6 
199 Metastatic_Solid_Tumor 6 
199 Metastatic_Solid_Tumor 6 
199.1 Metastatic_Solid_Tumor 6 
42 AIDS 6 
V08 AIDS 6 
496 Chronic_Pulmonary_Dz 1 
500 Chronic_Pulmonary_Dz 1 
501 
Chronic_Pulmonary_Dz 
1 
502 Chronic_Pulmonary_Dz 1 
503 Chronic_Pulmonary_Dz 1 
504 Chronic_Pulmonary_Dz 1 
505 Chronic_Pulmonary_Dz 1 
506.4 Chronic_Pulmonary_Dz 1 
710.1 Connective_tissue_Dz 1 
710.1 Connective_tissue_Dz 1 
710.2 Connective_tissue_Dz 1 
710.3 Connective_tissue_Dz 1 
710.4 Connective_tissue_Dz 1 
710.5 Connective_tissue_Dz 1 
710.8 Connective_tissue_Dz 1 
714 Connective_tissue_Dz 1 
714.1 Connective_tissue_Dz 1 
714.2 Connective_tissue_Dz 1 
714.81 Connective_tissue_Dz 1 
725 Connective_tissue_Dz 1 
196.1 Metastatic_Solid_Tumor 6 
196 Metastatic_Solid_Tumor 6 
456.21 Mod_Severe_Liver_Dz 3 
456.2 Mod_Severe_Liver_Dz 3 
456 Mod_Severe_Liver_Dz 3 
572.4 Mod_Severe_Liver_Dz 3 
572.2 Mod_Severe_Liver_Dz 3 
588 Mod_Severe_Renal_Dz 2 
588.1 Mod_Severe_Renal_Dz 2 
588.8 Mod_Severe_Renal_Dz 2 
588.81 Mod_Severe_Renal_Dz 2 
588.89 Mod_Severe_Renal_Dz 2 
588.9 Mod_Severe_Renal_Dz 2 
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196.3 Metastatic_Solid_Tumor 6 
196.5 Metastatic_Solid_Tumor 6 
196.6 Metastatic_Solid_Tumor 6 
196.8 Metastatic_Solid_Tumor 6 
196.9 Metastatic_Solid_Tumor 6 
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APPENDIX C   Survey 
 
Health Validation Study survey: 
Participant Number:  ___ 
Please circle or short answer this survey. 
 
1. Age __________ 
2. Gender   Male/Female 
3. Weight  ___________ 
Height   ___________ 
4. Has a doctor ever told you that you have diabetes or high blood sugar including 
borderline diabetes?                                                                         (Yes / No) 
 
5. Has a doctor ever told you that you that you have cancer or a malignant tumor, 
excluding minor skin cancers unless it was melanoma?       (Yes / No) 
 
 
6. Do you have a chronic lung disease (Emphysema/Chronic Bronchitis) that limits 
your usual activities or makes you need oxygen at home?                              (Yes / No) 
 
7. Has a doctor ever told you that you have congestive heart failure?     (Yes / No) 
8. Have you smoked cigarettes in the past week?         (Yes / No) 
If no: 
a. Never smoked  (Less than 100 cigarettes in your entire life)  (Yes ) 
b. Former smoker?  (Yes ) 
 
9. Because of a health or memory problem, do you have any difficulty with bathing or 
showering?               (Yes / No) 
 
10.   Because of a health or memory problem, do you have any difficulty with      
  managing your money- such as paying your bills and keeping track of expenses?     
                (Yes / No) 
11.   Because of a health problem do you have any difficulty with walking several    
  blocks?               (Yes / No) 
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12.   Because of a health or memory problem, do you have any difficulty with pulling  
  or pushing large objects like a living room chair?                                         (Yes / No) 
 
13.   In general, would you say your health is 
a. Excellent 
b. Very good 
c. Good 
d. Fair  
e. Poor 
 
14.   During the past 12 months, how many times were you hospitalized overnight? 
a. None 
b. Once 
c. Twice or more 
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